References
- Ahmad H, Khandelwal K, Pachauri SD, et al. (2014). Stability indicating studies on NMITLI118RT+ (standardized extract of Withania somnifera Dunal.). Pharmacogn Mag 10:227–33
- Anderson M. (1985). Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548–55
- Bederson JB, Pitts LH, Tsuji M, et al. (1986). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17:472–6
- Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. (2003). Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 30:399–404
- Chaurasiya ND, Sangwan RS, Misra LN, et al. (2009). Metabolic clustering of a core collection of Indian ginseng Withania somnifera Dunal through DNA, isoenzyme, polypeptide and withanolide profile diversity. Fitoterapia 80:496–505
- Colado MI, O’Shea E, Granados R, et al. (1997). Study of the neurotoxic effect of MDMA (“ectasy”) on 5-HT neurons in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827–33
- Demaerschalk BM, Hwang HM, Leung G. (2010). US cost burden of ischemic stroke: a systematic, literature review. Am J Manage Care 16:525–33
- Dhar RS, Verma V, Suri KA, et al. (2006). Phytochemical and genetic analysis in selected chemotypes of Withania somnifera. Phytochemistry 67:2269–76
- Dwivedi AK, Ahmad H, Khandelwal K, et al. (2014). A formulation useful for delivery of neuro protecting agent. Indian Patent Application Number 2773DEL2014, filed on 29.09.2014
- Gortzi O, Lalas S, Chinou I, Tsakins J. (2007). Reevaluation of bioactivity and antioxidant activity of Myrtus communis extract before and after encapsulation in liposomes. Eur Food Res Technol 226:583–90
- Gupta YK, Briyal S, Gulati A. (2010). Therapeutic potential of herbal drugs in cerebral ischemia. Indian J Physiol Pharmacol 54:99–122
- Ishii T, Asai T, Oyama D, et al. (2012). Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J control Release 160:81–7
- Ishii T, Asai T, Oyama D, et al. (2013). Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J 27:1362–70
- Lapchak PA, Schubert DR, Maher PA. (2010). Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem 116:122–31
- Longa EZ, Weinstein PR, Cummins R. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84–91
- National Stroke Association. (2013) Explaining stroke. p. 1–18, http://www.stroke.org/site/DocServer/ExplainingStroke_web.pdf?docID=3321 [last accessed 14 Aug 2014]
- Park SN, Lee MH, Kim SJ, Yu ER. (2013). Preparation of quercetin and rutin-loaded ceramide liposomes and drug-releasing effect in liposome-in-hydrogel complex system. Biochem Biophys Res Commun 435:361–6
- Rajasekar S, Elango R. (2011). Estimation of alkaloid content of Ashwagandha (Withania somnifera) with HPLC methods. J Exp Sci 2:39–41
- Ramos-Cabrer P, Agulla J, Argibay B, et al. (2011). Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm 405:228–33
- Rao MA, Hatcher JF, Tureyen K. (2005). CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res 1058:193–7